An interventional study of Acupuncture and Low-level laser therapy in Heart Failure and Acupuncture, sponsored by National Yang Ming Chiao Tung University Hospital. Completed at 1 site in Taiwan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2023-03-24.
Sponsored by National Yang Ming Chiao Tung University Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 137 studies in Heart Failure with a site in Taiwan — 30 open to participants now, 39 under way, 14 of them phase 3. Heart Failure · Taiwan.
Among the 137 studies in Heart Failure with a site in Taiwan, this one is the 98th largest by enrollment of the 101 interventional ones that give a count, is one of 5 that started in 2020, is one of 49 with no phase, and was the 64th registered.
6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.
Browse Heart Failure studies →30 of the 137 studies in Heart Failure with a site in Taiwan are open now. Recruiting first, the newest first:
AstraZeneca · Sites in Taiwan, United States, Argentina and 29 more countries
Ages 18+
Bayer · Sites in Taiwan, United States, Argentina and 20 more countries
Ages up to 18
Novo Nordisk A/S · Sites in Taiwan, United States, Argentina and 24 more countries
Ages 18+
National Defense Medical Center, Taiwan · Sites in Taiwan
Ages 20–90 · Healthy volunteers
National Taiwan University Hospital · Sites in Taiwan
Ages 18+
A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →
Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
137 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 11 · Phase 3 34 · Phase 4 9
First in 2006; this study’s year is marked. 5 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 17 is below the median of 76 across 4,053 interventional studies indexed under Heart Failure.
Median enrollment 177 across the 101 interventional studies, 200 across the 36 observational. Of the 73 that completed or were terminated, 35 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
51 of 137 have an industry lead sponsor. The 10 most frequent:
National Yang Ming Chiao Tung University Hospital is the lead sponsor of 11 studies on the registry; 3 are open to participants now.
National Yang Ming Chiao Tung University Hospital has 1 study filed under Heart Failure — fewer than ten, so there is no comparison to draw.
6 of the studies in Heart Failure with a site in Taiwan that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06307652Phase 3AstraZenecaStudy to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function | 2027-04-16 |
| NCT06008197Phase 3Colorado Prevention CenterA Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients | 2027-11 |
| NCT07068308National Yang Ming Chiao Tung UniversityEffects of a Wed-based FRAIL-SM Program Among Patients With Heart Failure | 2027-05-31 |
| NCT06968533National Defense Medical Center, TaiwanECG Low Ejection Fraction Detection and Guiding in AI Navigated Treatment Era | 2027-06-01 |
| NCT07798856Chimei Medical CenterEffects of a Multidisciplinary Integrated Care Model on Care Outcomes in Patients With Heart Failure With Preserved Ejection Fraction | 2027-07 |
Add all 6 to your calendar (.ics) → With an account.
Among the 137 studies in Heart Failure with a site in Taiwan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The advantages of laser acupuncture are a non-invasive, painless, low risk of infection and high safety. Laser acupuncture as a treatment tool has the following advantages1.Painless, 2. Non-invasive treatment, the subject is highly accepted, the risk of infection and needle stick is low, 3. Very few side effects such as fainting, bleeding, 4. The therapeutic dose is easy to operate, and the instrument output frequency, power and time can be controlled. Through the clinical physiological function test plus the verification and analysis of the quantitative test values, it will be more able to define the new role of laser acupuncture treatment in patients with heart failure from the perspective of Chinese medicine.
From the perspective of ancient books, the discussion of heart failure in the etiology and pathogenesis of traditional Chinese medicine was first seen in the "Shu Wen". It is clearly pointed out that "heart qi" is the basic pathogenesis of heart failure. The "qi" and "blood" of Chinese medicine are closely related. The blood line is driven by the gas, the blood is bloody, and the qi deficiency is unable to push the blood to blood. If the qi deficiency, it would lead to blood stasis; There were studies have indicated that traditional acupuncture treatment can increase exercise tolerance and adjust autonomic nerve activity in patients with chronic heart failure, and can reduce their readmission rate and mortality rate in patients with acute heart failure. Studies using laser acupuncture to treat patients with heart failure have also found that they can increase the subject's six-minute walking distance.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Low-level laser irradiation on specific acupuncture points
Device: Low-level laser therapy
Dry needle inserting specific acupuncture points
Procedure: Acupuncture
acupuncture at specific acupuncture points
low level laser emission on specific acupuncture points
N- terminal pro-brain natriuretic peptide, NT-proBNP
The change of NT-pro BNP from the date of admission to the end of trial
Time frame: At the 12th week and 24th week
High sensitivity C-Reactive Protein, hs-CRP Hs-CRP
The change of NT-pro BNP from the date of admission to the end of trial
Time frame: At the 12th week and 24th week
Questionnaires_Instrumental activities of daily living
(IADL);Scoring from 0 to 4 and higher scores mean better outcome.
Time frame: At the 4th, 12t, 20th and 24th week
Questionnaires_EuroQol- 5 Dimension
(EQ-5D);Scoring from 1 to 3 and higher scores mean better outcome.
Time frame: At the 4th, 12t, 20th and 24th week
Questionnaires_The Minnesota LIVING WITH HEART FAILURE® Questionnaire
(MLHFQ);Scoring from 0 to 5 and higher scores mean better outcome.
Time frame: At the 4th, 12t, 20th and 24th week
Questionnaires_Patient Health Questionnaire-9
(PHQ-9);Scoring from 0 to 3 and higher scores mean worse outcome.
Time frame: At the 4th, 12t, 20th and 24th week
Questionnaires_Constitution in Chinese Medicine Questionnaire
(CCMQ);Scoring from 1 to 5 and higher scores correspond to specific body constitution.
Time frame: At the 4th, 12th, 20th and 24th week
6 minutes walking test
(6 minutes walking distance, meters)
Time frame: At the 4th, 12t, 20th and 24th week
Left ventricular ejection fraction
(Ejection fraction, %)
Time frame: At the 24th week
Heart rate variability_SDNN
(Standard deviation of all normal to normal intervals, ms)
Time frame: At the 12th and 24th week
Heart rate variability_SDANN index
(Standard deviation of average normal to normal intervals index, ms)
Time frame: At the 12th and 24th week
Heart rate variability_ASDNN
(Average standard deviation of all 5-min R-R intervals, ms)
Time frame: At the 12th and 24th week
Heart rate variability_rMSSD
(The square root of the mean of the sum of the squares of differences between adjacent NN intervals, ms)
Time frame: At the 12th and 24th week
Heart rate variability_LF
(Low frequency power, normalized unit/ n.u. and ms2)
Time frame: At the 12th and 24th week
Heart rate variability_HF
(High frequency power, normalized unit/ n.u. and ms2)
Time frame: At the 12th and 24th week
Heart rate variability_LF/HF
(LF/HF Ratio)
Time frame: At the 12th and 24th week
Ran from Jul 2020 to primary completion in Dec 2022, 29 months.
Of 1,119 non-industry interventional studies with no phase under Heart Failure, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 50. This study's 29 months is close to that.
Counting every sponsor, half of 1,355 studies reached it within 31 months; a quarter within 16 and three quarters within 52.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
National Yang Ming Chiao Tung University Hospital